Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Measuring Chemotherapy Completion in Elderly Women

Gynecol Oncol; ePub 2017 Jan 14; von Gruenigen, et al

Elderly patients with ovarian, primary peritoneal, or fallopian tube cancer and with a higher baseline Instrumental Activities of Daily Living (IADL) score were more likely to complete 4 cycles of chemotherapy and less likely to experience grade III or higher toxicity, a recent study found. Patients aged ≥70 years were tested for the ability to complete 4 cycles of first-line chemotherapy without dose reductions or >7 days delay. Patients and their physicians chose between 2 regimens: CP (carboplatin AUC 5, paclitaxel 135 mg/m2), or C (carboplatin AUC 5), both given every 3 weeks either after primary surgery or as neoadjuvant thermotherapy with IADL and quality of life (QOL) assessments performed at baseline, pre-cycle 3, and post-cycle 4. Researchers found:

  • 212 women enrolled (152 selected CP and 60 selected C); those who selected CP had higher baseline IADL scores.
  • Baseline IADL was independently associated with choice of regimen.
  • Baseline IADL score was not associated with completion of 4 cycles of chemotherapy without dose reduction or delays but was associated with completion of 4 cycles regardless of dose reduction and delay and toxicity.
  • IADL was also associated with overall survival for patients receiving CP.


von Gruenigen VE, Huang HQ, Beumer JH, et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. [Published online ahead of print January 14, 2017]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.11.033.